Personalized GVHD Mitigation Systems

A next-generation system for mitigating graft versus host disease (GVHD) after hematopoietic cell transplantation (HCT) by leveraging AI-driven dosing regimens, genomic profiling, and real-time monitoring to provide personalized treatment and reduce the risk of GVHD.

The original patent disclosed methods for reducing the risk of GVHD after HCT by administering alpha-1 antitrypsin (A1AT) according to specific schedules. However, these methods have limitations, including the lack of personalized dosing and real-time monitoring. The new inventive concept addresses these limitations by introducing AI-driven dosing regimens, genomic profiling, and real-time monitoring to provide more effective and targeted treatment.

The new inventive concept comprises a system for mitigating GVHD, which includes a personalized, AI-driven dosing regimen of A1AT tailored to an individual patient's genomic profile. The dosing regimen is adjusted in real-time based on machine learning algorithms analyzing the patient's response to treatment. Additionally, the system includes a deep learning model for predicting the likelihood of GVHD onset, a nanosensor-based device for in vivo monitoring of A1AT levels, a method for generating personalized, 3D-printed implants, and a system for remote monitoring and management of GVHD.

The new claims introduce the use of AI-driven dosing regimens, genomic profiling, and real-time monitoring, which are not present in the original patent. The combination of these elements provides a novel and non-obvious approach to mitigating GVHD.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, genomic profiling techniques, or monitoring devices. Additionally, the system could be adapted for use in other types of transplantation or for treating other diseases.

The inventive concept has significant commercial potential in the field of hematopoietic cell transplantation, particularly in the treatment of GVHD. The system could be marketed to hospitals, research institutions, and pharmaceutical companies, with potential applications in personalized medicine, regenerative medicine, and remote patient monitoring.